Yahong Medicine (688176.SH) announced that recently, the company's product APL-1702 has been used to treat high-grade squamous intraepithelial lesions of the cervix...
According to the announcement from Yahong Medicine (688176.SH), the recent results of the company's prospective, randomized, double-blind, placebo-controlled international multicenter phase III clinical trial of APL-1702 for the treatment of high-grade squamous intraepithelial lesions of the cervix (HSIL) have been selected for presentation at the 2024 International Photodynamic Therapy & Photodiagnosis update conference (PDT&PD). The efficacy data of this study, specifically in reducing the pathological grading of cervical cancer precursor lesions, will be presented in the form of an oral presentation at the conference.
APL-1702 is a photodynamic therapy product that combines pharmaceuticals and medical devices. It is used as a local non-surgical treatment for HSIL. The product consists of APL-1702 ointment (with 5% HAL·HCl as the active ingredient) and APL-1702 CL7 medical device (a cervical photodynamic therapy cup for intra-vaginal use, with LED red light as the treatment source).
